Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Rhea-AI Summary

Nuwellis (Nasdaq: NUWE) entered a definitive securities purchase agreement with institutional investors for a registered direct offering of 1,310,890 common shares at $2.59 per share, for approximately $3.4 million in gross proceeds, priced at-the-market under Nasdaq rules.

According to Nuwellis, it also received about $3.1 million in gross proceeds from the exercise of warrants issued in its June 2026 public offering. In a concurrent private placement, investors will receive five-year warrants to purchase up to 1,310,890 additional shares at $2.59 per share. Closing is expected on or about August 3, 2026, subject to customary conditions, with Ladenburg Thalmann acting as exclusive placement agent.

Positive

• $3.4 million gross proceeds from registered direct offering of 1,310,890 shares at $2.59
• $3.1 million additional gross proceeds from exercise of June 2026 offering warrants
• Additional 1,310,890 five-year warrants at $2.59 may provide future capital if exercised

Negative

• Issuance of 1,310,890 new shares results in immediate equity dilution for existing holders
• Concurrent private placement adds 1,310,890 new warrants, creating potential further dilution if exercised

Market Context

The platform's offering history shows an average 24-hour move of -16.19%, providing a relevant finan...

Analysis

The platform's offering history shows an average 24-hour move of -16.19%, providing a relevant financing comparison. The active S-3 is a resale registration, while moderate short positioning adds a risk factor to monitor alongside warrant terms.

Key Figures

Offering Size: $3.4M Shares Offered: 1,310,890 shares Offering Price: $2.59 per share +5 more

8 metrics

Offering Size $3.4M registered direct offering

Shares Offered 1,310,890 shares common stock

Offering Price $2.59 per share at-the-market pricing

Warrant Exercise Proceeds $3.1M gross proceeds from previously issued warrant exercises

Warrant Shares 1,310,890 shares shares underlying concurrent private-placement warrants

Warrant Term 5 years from registration statement effectiveness

Expected Closing August 3, 2026 subject to customary closing conditions

S-3 Effectiveness July 9, 2024 shelf registration statement declared effective by the SEC

Previous Offering Reports

5 past events · Latest: Jun 08 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 08	Registered public offering	Positive	+0.1%	Offering closed with approximately $6.0 million in gross proceeds.
Jun 05	Public offering pricing	Negative	-61.2%	Offering priced at $0.30 per share with accompanying warrants.
Jun 10	Underwritten public offering	Positive	+57.6%	Offering closed with full exercise of the overallotment option.
Jun 09	Underwritten public offering	Negative	-42.9%	Company priced a $4.3 million offering with accompanying warrants.
Nov 05	Warrant exercise	Negative	-34.5%	Warrant exercises generated $5.1 million in gross proceeds.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Offering-tagged history showed negative reactions in three events and positive reactions in two, with an average move of -16.19%.

Key Terms

registered direct offering, at-the-market, private placement, shelf registration statement, +2 more

6 terms

registered direct offering financial

"purchase and sale of 1,310,890 shares of the Company’s common stock"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

at-the-market financial

"in a registered direct offering priced at-the-market under Nasdaq rules"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

private placement financial

"in a concurrent private placement, the Company will issue"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

shelf registration statement regulatory

"being offered pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 (File No. 333-280647)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

regulation d regulatory

"and Regulation D promulgated thereunder"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public Offering

MINNEAPOLIS, July 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company’s common stock at a price of $2.59 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

Nuwellis also received approximately $3.1 Million in gross proceeds from the exercise of previously issued warrants which were issued in connection with the Company’s June 2026 public offering.

In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 1,310,890 shares of common stock. The warrants have an exercise price of $2.59 per share, will be exercisable immediately following the date of issuance and will have a term of five years from the date of effectiveness of the registration statement for the purposes of registering the shares of common stock underlying the warrants.

The closing of the registered direct offering and the concurrent private placement is expected to occur on or about August 3, 2026, subject to the satisfaction of customary closing conditions.

Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offerings.

The securities described above (excluding the warrants and the shares of common stock underlying the warrants) are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-280647), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on July 9, 2024. The registered direct offering is being made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement, that will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.

The warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying such warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and the underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, without limitation, statements with respect to the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds from the offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the offerings, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Relations:
CORE IR
ir@nuwellis.com

Media Contact:
CORE PR
media@nuwellis.com

FAQ

What did Nuwellis (NUWE) announce in its $3.4 million registered direct offering on July 31, 2026?

Nuwellis announced a registered direct offering of 1,310,890 common shares at $2.59 per share, raising about $3.4 million in gross proceeds. According to Nuwellis, this deal is priced at-the-market under Nasdaq rules and targets certain institutional investors.

How many new shares and warrants are included in the July 2026 Nuwellis (NUWE) financing?

The financing includes 1,310,890 newly issued common shares and warrants to purchase up to 1,310,890 additional shares. According to Nuwellis, the warrants carry a $2.59 exercise price, are immediately exercisable, and have a five-year term from registration effectiveness.

What additional capital did Nuwellis (NUWE) receive from warrant exercises related to its June 2026 public offering?

Nuwellis received approximately $3.1 million in gross proceeds from the exercise of previously issued warrants tied to its June 2026 public offering. According to Nuwellis, this warrant exercise funding is separate from the new $3.4 million registered direct equity raise.

When is the closing of Nuwellis’ July 2026 registered direct offering and private placement expected?

The closing of the registered direct offering and concurrent private placement is expected on or about August 3, 2026. According to Nuwellis, completion remains subject to the satisfaction of customary closing conditions associated with these institutional financing transactions.

What are the terms of the new Nuwellis (NUWE) warrants issued in the July 2026 private placement?

The new warrants allow purchase of up to 1,310,890 shares at an exercise price of $2.59 per share. According to Nuwellis, they are immediately exercisable and will remain outstanding for five years from the effectiveness of the related registration statement.